Oral pharmacological chaperones to restore phenylalanine hydroxylase activity in phenylketonuria
Vireo Therapeutics (fictional) · Principal Investigator: [PI name]
Phenylketonuria (PKU) is an inherited disorder in which loss of phenylalanine hydroxylase (PAH) activity allows phenylalanine (Phe) to build up in the blood and brain. Untreated, high Phe causes lasting cognitive and behavioral harm. Most people with PKU manage the condition with a lifelong, highly restrictive low-protein diet that is difficult to sustain, especially in adolescence and adulthood. Current oral drug therapy helps only a subset of patients, and the injectable enzyme therapy carries a boxed warning for anaphylaxis.
Many disease-causing PAH variants are misfolding variants: the enzyme is made, but it is unstable and degraded before it can work. A small molecule that binds and stabilizes these variants could restore enough activity to lower blood Phe with a daily pill. Vireo has identified three chemically distinct hits that increase the thermal stability of misfolding PAH variants in vitro (illustrative preliminary data). The objective of this Phase I project is to establish whether these hits restore PAH activity in human cells, the critical step before medicinal chemistry optimization. Our central hypothesis is that chaperone binding increases the amount of functional PAH in cells carrying misfolding variants, raising Phe-to-tyrosine conversion.
Aim 1. Quantify stabilization and activity rescue across common misfolding PAH variants. We will measure thermal stability and steady-state enzyme kinetics (Km, Vmax) of purified PAH variants, including R261Q and Y414C, with and without each hit compound. Milestone: at least one hit increases variant melting temperature by ≥2 °C and restores ≥20% of wild-type activity in vitro.
Aim 2. Test rescue of PAH protein levels and Phe metabolism in human hepatocyte models. We will express misfolding variants in a human hepatocyte cell line and measure PAH protein levels, cellular Phe-to-tyrosine conversion, and cell viability across a dose range. Milestone: a dose-dependent increase in PAH protein and tyrosine production at non-toxic concentrations, supporting a Phase II lead-optimization and in vivo program.
Expected outcomes and impact
Completion of these aims will identify a validated chaperone scaffold and the variant groups most likely to respond, defining the patient population for development. An effective oral chaperone could lower blood Phe for many people with misfolding variants, easing dietary restriction and improving long-term neurological outcomes.
Fictional company and illustrative preliminary data, created as a writing sample. Disease background reflects published literature; no real compounds or results are described.